A5044434305- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cancer Genomics and Diagnostics
- Chronic Disease Management Strategies
- Renal and related cancers
City of Hope
2019-2023
Royal College of Physicians
2017
678 Background: Recent studies have suggested an association between the time-of-day of ICI infusions and disease outcomes, including progression free survival overall survival, among patients with cancer. (Qian et al Lancet Oncology 2021). We sought to identify whether such exists in mRCC receiving ICIs. Methods: Patients treated nivolumab alone, or combination ipilimumab, either first- second-line treatment were retrospectively identified. who received <25% after 4:30 pm assigned early...
<h3>Introduction</h3> Clinical trials suggest attendance at PR reduces subsequent hospitalisation rates. However, whether this benefit occurs in routine clinical practice is uncertain. We analysed admission rates and days spent hospital 90 180 after assessment for the 2015 national audit cohort. <h3>Methods</h3> services across England Wales provided data all consenting patients assessed between Jan April 2015. Cumulative of to numbers each timepoint (and day timepoints) were extracted from...